Application of ganglioside receptor for Theileria sergenti on the bovine erythrocytes to the prevention and treatment of bovine thelleriosis.

牛红细胞上塞氏泰勒虫神经节苷脂受体在防治牛泰勒虫病中的应用。

• 批准号: 08660364
• 负责人: WATARAI Shinobu
• 金额: $ 1.66万
• 依托单位: Okayama University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08660364/
• 关键词: Bovine theileriosis; Theileria sergenti; Receptor; Ganglioside; Clycolipid; Liposome; Monoclonal antibody

Ganglioside receptor on the bovine erythrocytes was qpplied to the prevention and treatment of bovine theileriosis.1. Production of monocional antibody against gangliosiode receptor, 1-active ganglioside (NeuGc), on the bovine erythrocytes for T.sergentl.Monoclonal antibody against I-active ganglioside (NeuGc), SHS-21, of the IgM class was obtained by the immunization of BALB/c mice with bovine erythrocytes-derived I-active ganglioside (NeuGc) inserted into liposomes with Salmonella minnesota R595 lipopolysaccharides. Various purified gangliosides were used to determine the specificity of the monoclonal antibody. SHS-21 antibody was found to react with I-active ganglioside (NeuGc) and i-active ganglioside (NeuGc), but not with other gangliosides tested. It has been shown that I-active ganglioside (NeuGc) on the bovine erythrocytes surface was suggested to act as attachment side for T.sergenti merozoites. Thus, SHS-21 antibody is considered to be useful for the treatment of bovine theil … More eriosis.2. Preparation of drug-laden liposomes containing I-active ganglioside (NeuGc).To elucidate whether or not antiprotozoan agent-laden liposomes having I-active ganglioside (NeuGc) are able to prepare, experiment was performed. The result of the experiment was that I-active ganglioside (NeuGc) incorporated liposomes are able to encapsulate the antiprotozoan agent. This type of liposomes may lead to new approaches to the treatment of bovine theileriosis.3. Application of liposomes containing I-active gangliosiode (NeuGc) for development of bovine theileriosis vaccines.In order to evaluate the usefulness of liposomes containing I-active ganglioside (NeuGc) as oral vaccines for bovine theileriosis, the stability of liposomes and antibody responses to ganglioside antigen associated with liposomes after oral administration were examined. Liposomes composed of dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylserine (DPPS), and cholesterol (Chol) (1 : 1 : 2, molar ratio), distearoylphosphatidylchollne (DSPC) nd Chol (7 : 2, molar ratio), and DSPC,DPPS,and Chol (7 : 3 : 2 or 1 : 1 : 2, molar ratio) were stable in acidic solution (pH 2.0), bile, and pancreatin solution. After the oral immunization of ganglioside antigen (ganglioside GM1) -containing liposomes composed of DPPC,DPPS,and Chol (1 : 1 : 2, molar ratio) to mice, the serum IgA antibody responses against ganglioside GM1 were found. On the other hand, such liposomes were unable to induce any detectable anti-ganglioside GM1 IgG and IgM antibody responses by oral administration. In future, further studies will be necessary to develop the liposomes for the generation of serum IgG or IgM responses by oral immunization. Less

牛红细胞神经节苷脂受体在牛泰勒虫病防治中的应用.制备抗牛红细胞神经节苷脂受体1-活性神经节苷脂（NeuGc）的单克隆抗体SHS-21。各种纯化的神经节苷脂用于确定单克隆抗体的特异性。SHS-21抗体与I-活性神经节苷脂（NeuGc）和I-活性神经节苷脂（NeuGc）反应，但与其他神经节苷脂不反应。牛红细胞表面的I-活性神经节苷脂（NeuGc）被认为是瑟氏锥虫裂殖子的附着面。因此，认为SHS-21抗体可用于治疗牛泰尔病。 ...更多信息 毛化。含有I-活性神经节苷脂（NeuGc）的载药脂质体的制备为了阐明是否能够制备具有I-活性神经节苷脂（NeuGc）的载抗原动物剂脂质体，进行了实验。实验的结果是，I-活性神经节苷脂（NeuGc）掺入脂质体能够封装抗原动物剂。这种类型的脂质体可能会导致新的方法来治疗牛泰勒虫病。含I-活性神经节苷脂（NeuGc）的脂质体在牛泰勒虫病疫苗开发中的应用为了评价含I-活性神经节苷脂（NeuGc）的脂质体作为牛泰勒虫病口服疫苗的有效性，检查了脂质体的稳定性以及口服给药后对脂质体相关神经节苷脂抗原的抗体反应。由二棕榈酰磷脂酰胆碱（DPPC）、二棕榈酰磷脂酰丝氨酸（DPPS）和胆固醇（Chol）（摩尔比1：1：2）、二硬脂酰磷脂酰胆碱（DSPC）和Chol（摩尔比7：2）以及DSPC、DPPS和Chol（摩尔比7：3：2或1：1：2）组成的脂质体在酸性溶液（pH 2.0）、胆汁和胰酶溶液中稳定。由DPPC、DPPS和Chol（摩尔比为1：1：2）组成的含有神经节苷脂抗原（神经节苷脂GM 1）的脂质体经口免疫小鼠后，发现血清中存在抗神经节苷脂GM 1的伊加抗体应答，而口服该脂质体不能诱导任何可检测到的抗神经节苷脂GM 1的IgG和IgM抗体应答。在未来，进一步的研究将是必要的，以开发脂质体的产生血清IgG或IgM的反应，通过口服免疫。少

项目成果

Watarai, S.: "Isolation and characterization of gangliosides from Theileria sergenti." J.Vet.Med.Sci.58・11. 1099-1105 (1996)

Watarai, S.：“塞氏泰勒菌的神经节苷脂的分离和表征”，J.Vet.Med.Sci.58·11（1996）。

Watarai, S.: "Isolation and characterization of gangliosides from Thelleria sergenti." J.Vet.Med.Sci.58-11. 1099-105 (1996)

Watarai, S.：“瑟氏泰勒菌神经节苷脂的分离和表征。”

Maehara, T.: "A monocional antibody that recognizes ganglioside GD1b in the rat central nervous system." Neuropathology. 17. 284-289 (1997)

Maehara, T.：“一种单克隆抗体，可识别大鼠中枢神经系统中的神经节苷脂 GD1b。”

乾 梅、渡来 仁・他: "リポソームを応用した経口ワクチンの開発:経口投与可能なリポソームによる免疫応答" 日本DDS学会誌. 13・1. 13-20 (1998)

Ume Inui、Hitoshi Watari 等：“使用脂质体的口服疫苗的开发：口服脂质体的免疫反应”日本 DDS 学会杂志 13・1（1998 年）。

Kawai, K.: "Ganglioside GD3 of cerebral neurons and Purkinje cells in aged human brains." Neurosci.Res.29. 9-16 (1997)

Kawai, K.：“老年人大脑中大脑神经元和浦肯野细胞的神经节苷脂 GD3。”